Fractyl Health Inc (GUTS) Actualités

Fractyl Health to Present at Chardan’s 8th Annual Genetic Medicines Conference

BURLINGTON, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a...

Fractyl Health to Participate in Upcoming September Investor Conferences

BURLINGTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a...

Form 8-K - Current report

Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates

Updated clinical results from German Real-World Registry demonstrate potential for Revita® to meaningfully...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Fractyl Health Announces Clinical Results from German Real-World Registry Showing Meaningful and Sustained Weight Loss for at Least One Year After a Single Revita® Endoscopic Procedure

Median weight decreased from 111 kilograms (245 pounds) to 97 kilograms (214 pounds), representing nearly 13...

Fractyl Health to Report Second Quarter 2024 Financial Results and Provide Business Updates on August 14, 2024

BURLINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a...

Form 8-K - Current report

Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs

Breakthrough Device Designations are granted by the U.S. FDA to expedite review of promising technologies that...

Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day

BURLINGTON, Mass., June 25, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a...

Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates

Company will accelerate Revita® weight maintenance clinical study REMAIN-1; open label data from REVEAL-1...

Fractyl Health to Present New Preclinical Obesity Data from Rejuva® Platform at the American Diabetes Association’s 84th Scientific Sessions

BURLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a...

Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024

Results showed single-administration GLP-1 pancreatic gene therapy candidate reduced liver weight by 42...

Form 3/A - Initial statement of beneficial ownership of securities: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]